Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Janux Therapeutics, Inc. (Nasdaq: JANX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other periodic filings. As a clinical-stage biopharmaceutical company focused on tumor-activated immunotherapies, Janux uses these filings to report financial results, business updates and certain corporate events.
Form 8-K filings for Janux include items such as the public release of quarterly financial results under Item 2.02, where the company furnishes press releases summarizing collaboration revenue, research and development expenses, general and administrative expenses, and net loss for specific reporting periods. Other 8-Ks address corporate matters under Item 5.02, such as changes in executive roles or departures of certain officers, along with references to relevant compensation or severance arrangements.
For investors analyzing JANX, the full SEC record also encompasses annual reports on Form 10-K, quarterly reports on Form 10-Q, and any registration statements or proxy materials the company may file. These documents typically provide details on the TRACTr, TRACIr and ARM platforms, risk factors related to clinical development, descriptions of the JANX007 and JANX008 clinical programs, and information on collaborations, including the TRACTr agreement with Merck.
On Stock Titan, Janux filings are updated as new documents are posted to EDGAR, and each entry can be paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to earnings, pipeline updates, or corporate governance, and can review the underlying text when deeper due diligence is required. This page also provides a convenient route to track any future insider transaction reports on Form 4, as well as proxy statements that may discuss executive compensation and governance policies.
Point72 affiliates and Steven A. Cohen report beneficial ownership of 3,069,759 shares of Janux Therapeutics common stock, representing 5.0% of the class as of April 28, 2026. The holdings are reported by Point72 Asset Management, L.P.; Point72 Capital Advisors, Inc.; and Steven A. Cohen under a joint filing agreement. The filing states the reporting persons own no shares directly and that shared voting and dispositive power over 3,069,759 shares is held through Point72 Associates, an investment fund managed by Point72 Asset Management.
Janux Therapeutics reported a Schedule 13G showing Point72 entities and Steven A. Cohen beneficially hold 5.0% of common stock.
The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over 3,069,759 shares as of April 28, 2026. The holders report no sole voting or dispositive power and identify a Joint Filing Agreement (Exhibit 99.1).
Janux Therapeutics, Inc. changed the board class designation of director Eric Dobmeier to rebalance its staggered board. On April 28, 2026, Dobmeier resigned as a Class III director, whose term would have run until the 2027 Annual Meeting of Stockholders, and was immediately reappointed as a Class II director, whose term runs until the 2026 Annual Meeting.
The company states his board service is treated as continuous for all purposes, including vesting and settlement of any outstanding equity awards and other non-employee director compensation. Dobmeier will continue serving on the Board’s Compensation Committee.
Janux Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 11, 2026 at 1:30 p.m. Pacific Time. Holders of 60,961,546 shares of common stock outstanding as of the April 17, 2026 record date are entitled to vote.
Stockholders will elect two Class II directors, Natasha Hernday and Eric Dobmeier, to three-year terms ending at the 2029 meeting. Two current Class II directors, Sheila Gujrathi, M.D. and Alana McNulty, are not standing for re‑election, reducing the Board to seven members.
Investors are also being asked to ratify Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and to approve, on an advisory basis, the compensation of named executive officers. The Board recommends voting “FOR” all three proposals. The proxy details Board independence, committee structure, auditor fees and an executive pay program emphasizing performance-based incentives aligned with corporate goals.
JANX filing a Form 144 noting proposed sales of Common Stock under Rule 144 and exercises under a registered plan. The filing lists two past dispositions by Andy Meyer: 118,122 shares sold on 01/23/2026 for $1,738,389.66 and 178,767 shares sold on 01/26/2026 for $2,601,113.48. The excerpt also references option exercises dated 04/13/2026.
JANX notice of proposed sale of Common Stock under Section 144 related procedures. The submission lists 71,016 shares tied to an exercise of options under a registered plan dated 04/02/2026 and 3,786 shares from restricted stock vesting dated 01/01/2026. The excerpt also records a 2,714-share sale on 01/02/2026 generating $37,263.22.
Janux Therapeutics files its annual report describing a clinical‑stage pipeline built on proprietary TRACTr, TRACIr and ARM platforms for oncology and autoimmune diseases. The company focuses on tumor‑activated T‑cell engagers designed to reduce cytokine release syndrome, limit healthy‑tissue toxicity and extend half‑life.
Lead programs include PSMA‑targeted JANX007 for metastatic castration‑resistant prostate cancer, EGFR‑targeted JANX008 for solid tumors, and CD19‑targeted JANX011 for autoimmune indications. Janux also highlights collaborations with Merck and Bristol Myers Squibb and reports approximately $1.1 billion non‑affiliate market value and 60,831,656 shares outstanding.
Janux Therapeutics filed an 8-K to share fourth-quarter and full-year 2025 results and a business update. The company ended December 31, 2025 with $966.6 million in cash, cash equivalents and short-term investments, down from $1.03 billion a year earlier, providing substantial funding for its pipeline.
Research and development expenses rose to $125.9 million in 2025 from $68.4 million in 2024, while general and administrative expenses were roughly flat at $41.8 million versus $41.0 million. Net loss widened to $157.7 million from $69.0 million, reflecting heavier investment in clinical programs.
Operationally, Janux highlighted continued progress for TRACTr candidates JANX007 in metastatic castration-resistant prostate cancer and JANX008 in solid tumors, as well as the Phase 1 start of JANX011 in healthy volunteers. The company also announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb, including $50 million in upfront and near-term milestone payments and the potential for approximately $800 million in additional milestones plus tiered royalties.
Janus Henderson Group plc reported beneficial ownership of 5,350,453 shares of Janux Therapeutics, Inc. common stock, representing 8.9% of the class. The shares are held through various affiliated asset managers that exercise shared voting and investment power on behalf of their client accounts.
The filing explains that these asset managers manage multiple managed portfolios, such as funds and separate accounts, which actually receive all dividends and sale proceeds from the Janux shares. None of the individual managed portfolios owns more than 5% of Janux’s outstanding common stock.